Status: Recruiting
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms
Participants needed: 25
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: University of North Carolina, Chapel HillUpdated: Jan 30, 2026Locations: 5
Eligibility criteria
Informed consent will be obtained before any study-related procedures [+7]
Prior exposure to mirikizumab [+11]